Caffeine	0	8	B-Drug_or_compound
inhibits	9	17	O
adenosine	18	27	B-Drug_or_compound
-	27	28	O
induced	28	35	O
accumulation	36	48	O
of	49	51	O
hypoxia	52	59	B-Gene_or_gene_product
-	59	60	I-Gene_or_gene_product
inducible	60	69	I-Gene_or_gene_product
factor	70	76	I-Gene_or_gene_product
-	76	77	I-Gene_or_gene_product
1alpha	77	83	I-Gene_or_gene_product
,	83	84	O
vascular	85	93	B-Gene_or_gene_product
endothelial	94	105	I-Gene_or_gene_product
growth	106	112	I-Gene_or_gene_product
factor	113	119	I-Gene_or_gene_product
,	119	120	O
and	121	124	O
interleukin	125	136	B-Gene_or_gene_product
-	136	137	I-Gene_or_gene_product
8	137	138	I-Gene_or_gene_product
expression	139	149	O
in	150	152	O
hypoxic	153	160	O
human	161	166	B-Organism
colon	167	172	B-Cell
cancer	173	179	I-Cell
cells	180	185	I-Cell
.	185	186	O

Frequent	188	196	O
coffee	197	203	O
consumption	204	215	O
has	216	219	O
been	220	224	O
associated	225	235	O
with	236	240	O
a	241	242	O
reduced	243	250	O
risk	251	255	O
of	256	258	O
colorectal	259	269	B-Pathological_formation
cancer	270	276	I-Pathological_formation
in	277	279	O
a	280	281	O
number	282	288	O
of	289	291	O
case	292	296	O
-	296	297	O
control	297	304	O
studies	305	312	O
.	312	313	O

Coffee	314	320	O
is	321	323	O
a	324	325	O
leading	326	333	O
source	334	340	O
of	341	343	O
methylxanthines	344	359	B-Drug_or_compound
,	359	360	O
such	361	365	O
as	366	368	O
caffeine	369	377	B-Drug_or_compound
.	377	378	O

The	379	382	O
induction	383	392	O
of	393	395	O
vascular	396	404	B-Gene_or_gene_product
endothelial	405	416	I-Gene_or_gene_product
growth	417	423	I-Gene_or_gene_product
factor	424	430	I-Gene_or_gene_product
(	431	432	O
VEGF	432	436	B-Gene_or_gene_product
)	436	437	O
and	438	441	O
interleukin	442	453	B-Gene_or_gene_product
-	453	454	I-Gene_or_gene_product
8	454	455	I-Gene_or_gene_product
(	456	457	O
IL	457	459	B-Gene_or_gene_product
-	459	460	I-Gene_or_gene_product
8	460	461	I-Gene_or_gene_product
)	461	462	O
is	463	465	O
an	466	468	O
essential	469	478	O
feature	479	486	O
of	487	489	O
tumor	490	495	B-Pathological_formation
angiogenesis	496	508	O
,	508	509	O
and	510	513	O
the	514	517	O
hypoxia	518	525	B-Gene_or_gene_product
-	525	526	I-Gene_or_gene_product
inducible	526	535	I-Gene_or_gene_product
factor	536	542	I-Gene_or_gene_product
-	542	543	I-Gene_or_gene_product
1	543	544	I-Gene_or_gene_product
(	545	546	O
HIF	546	549	B-Gene_or_gene_product
-	549	550	I-Gene_or_gene_product
1	550	551	I-Gene_or_gene_product
)	551	552	O
transcription	553	566	O
factor	567	573	O
is	574	576	O
known	577	582	O
to	583	585	O
be	586	588	O
a	589	590	O
key	591	594	O
regulator	595	604	O
of	605	607	O
this	608	612	O
process	613	620	O
.	620	621	O

In	622	624	O
this	625	629	O
study	630	635	O
,	635	636	O
we	637	639	O
investigated	640	652	O
the	653	656	O
effects	657	664	O
of	665	667	O
caffeine	668	676	B-Drug_or_compound
on	677	679	O
HIF	680	683	B-Gene_or_gene_product
-	683	684	I-Gene_or_gene_product
1	684	685	I-Gene_or_gene_product
protein	686	693	O
accumulation	694	706	O
and	707	710	O
on	711	713	O
VEGF	714	718	B-Gene_or_gene_product
and	719	722	O
IL	723	725	B-Gene_or_gene_product
-	725	726	I-Gene_or_gene_product
8	726	727	I-Gene_or_gene_product
expression	728	738	O
in	739	741	O
the	742	745	O
human	746	751	B-Organism
colon	752	757	B-Cell
cancer	758	764	I-Cell
cell	765	769	I-Cell
line	770	774	I-Cell
HT29	775	779	I-Cell
under	780	785	O
hypoxic	786	793	O
conditions	794	804	O
.	804	805	O

Our	806	809	O
results	810	817	O
show	818	822	O
that	823	827	O
caffeine	828	836	B-Drug_or_compound
significantly	837	850	O
inhibits	851	859	O
adenosine	860	869	B-Drug_or_compound
-	869	870	O
induced	870	877	O
HIF	878	881	B-Gene_or_gene_product
-	881	882	I-Gene_or_gene_product
1alpha	882	888	I-Gene_or_gene_product
protein	889	896	O
accumulation	897	909	O
in	910	912	O
cancer	913	919	B-Cell
cells	920	925	I-Cell
.	925	926	O

We	927	929	O
show	930	934	O
that	935	939	O
HIF	940	943	B-Gene_or_gene_product
-	943	944	I-Gene_or_gene_product
1alpha	944	950	I-Gene_or_gene_product
and	951	954	O
VEGF	955	959	B-Gene_or_gene_product
are	960	963	O
increased	964	973	O
through	974	981	O
A3	982	984	B-Gene_or_gene_product
adenosine	985	994	I-Gene_or_gene_product
receptor	995	1003	I-Gene_or_gene_product
stimulation	1004	1015	O
,	1015	1016	O
whereas	1017	1024	O
the	1025	1028	O
effects	1029	1036	O
on	1037	1039	O
IL	1040	1042	B-Gene_or_gene_product
-	1042	1043	I-Gene_or_gene_product
8	1043	1044	I-Gene_or_gene_product
are	1045	1048	O
mediated	1049	1057	O
via	1058	1061	O
the	1062	1065	O
A2B	1066	1069	B-Gene_or_gene_product
subtype	1070	1077	O
.	1077	1078	O

Pretreatment	1079	1091	O
of	1092	1094	O
cells	1095	1100	B-Cell
with	1101	1105	O
caffeine	1106	1114	B-Drug_or_compound
significantly	1115	1128	O
reduces	1129	1136	O
adenosine	1137	1146	B-Drug_or_compound
-	1146	1147	O
induced	1147	1154	O
VEGF	1155	1159	B-Gene_or_gene_product
promoter	1160	1168	B-DNA_domain_or_region
activity	1169	1177	O
and	1178	1181	O
VEGF	1182	1186	B-Gene_or_gene_product
and	1187	1190	O
IL	1191	1193	B-Gene_or_gene_product
-	1193	1194	I-Gene_or_gene_product
8	1194	1195	I-Gene_or_gene_product
expression	1196	1206	O
.	1206	1207	O

The	1208	1211	O
mechanism	1212	1221	O
of	1222	1224	O
caffeine	1225	1233	B-Drug_or_compound
seems	1234	1239	O
to	1240	1242	O
involve	1243	1250	O
the	1251	1254	O
inhibition	1255	1265	O
of	1266	1268	O
the	1269	1272	O
extracellular	1273	1286	B-Gene_or_gene_product
signal	1287	1293	I-Gene_or_gene_product
-	1293	1294	I-Gene_or_gene_product
regulated	1294	1303	I-Gene_or_gene_product
kinase	1304	1310	I-Gene_or_gene_product
1	1311	1312	I-Gene_or_gene_product
/	1312	1313	O
2	1313	1314	B-Gene_or_gene_product
(	1315	1316	O
ERK1	1316	1320	B-Gene_or_gene_product
/	1320	1321	O
2	1321	1322	B-Gene_or_gene_product
)	1322	1323	O
,	1323	1324	O
p38	1325	1328	B-Gene_or_gene_product
,	1328	1329	O
and	1330	1333	O
Akt	1334	1337	B-Gene_or_gene_product
,	1337	1338	O
leading	1339	1346	O
to	1347	1349	O
a	1350	1351	O
marked	1352	1358	O
decrease	1359	1367	O
in	1368	1370	O
adenosine	1371	1380	B-Drug_or_compound
-	1380	1381	O
induced	1381	1388	O
HIF	1389	1392	B-Gene_or_gene_product
-	1392	1393	I-Gene_or_gene_product
1alpha	1393	1399	I-Gene_or_gene_product
accumulation	1400	1412	O
,	1412	1413	O
VEGF	1414	1418	B-Gene_or_gene_product
transcriptional	1419	1434	O
activation	1435	1445	O
,	1445	1446	O
and	1447	1450	O
VEGF	1451	1455	B-Gene_or_gene_product
and	1456	1459	O
IL	1460	1462	B-Gene_or_gene_product
-	1462	1463	I-Gene_or_gene_product
8	1463	1464	I-Gene_or_gene_product
protein	1465	1472	O
accumulation	1473	1485	O
.	1485	1486	O

From	1487	1491	O
a	1492	1493	O
functional	1494	1504	O
perspective	1505	1516	O
,	1516	1517	O
we	1518	1520	O
observe	1521	1528	O
that	1529	1533	O
caffeine	1534	1542	B-Drug_or_compound
also	1543	1547	O
significantly	1548	1561	O
inhibits	1562	1570	O
the	1571	1574	O
A3	1575	1577	B-Gene_or_gene_product
receptor	1578	1586	I-Gene_or_gene_product
-	1586	1587	O
stimulated	1587	1597	O
cell	1598	1602	B-Cell
migration	1603	1612	O
of	1613	1615	O
colon	1616	1621	B-Cell
cancer	1622	1628	I-Cell
cells	1629	1634	I-Cell
.	1634	1635	O

Conditioned	1636	1647	O
media	1648	1653	O
prepared	1654	1662	O
from	1663	1667	O
colon	1668	1673	B-Cell
cells	1674	1679	I-Cell
treated	1680	1687	O
with	1688	1692	O
an	1693	1695	O
adenosine	1696	1705	B-Drug_or_compound
analog	1706	1712	O
increased	1713	1722	O
human	1723	1728	B-Cell
umbilical	1729	1738	I-Cell
vein	1739	1743	I-Cell
endothelial	1744	1755	I-Cell
cell	1756	1760	I-Cell
migration	1761	1770	O
.	1770	1771	O

These	1772	1777	O
data	1778	1782	O
provide	1783	1790	O
evidence	1791	1799	O
that	1800	1804	O
adenosine	1805	1814	B-Drug_or_compound
could	1815	1820	O
modulate	1821	1829	O
the	1830	1833	O
migration	1834	1843	O
of	1844	1846	O
colon	1847	1852	B-Cell
cancer	1853	1859	I-Cell
cells	1860	1865	I-Cell
by	1866	1868	O
an	1869	1871	O
HIF	1872	1875	B-Gene_or_gene_product
-	1875	1876	I-Gene_or_gene_product
1alpha	1876	1882	I-Gene_or_gene_product
/	1882	1883	O
VEGF	1883	1887	B-Gene_or_gene_product
/	1887	1888	O
IL	1888	1890	B-Gene_or_gene_product
-	1890	1891	I-Gene_or_gene_product
8	1891	1892	I-Gene_or_gene_product
-	1892	1893	O
dependent	1893	1902	O
mechanism	1903	1912	O
and	1913	1916	O
that	1917	1921	O
caffeine	1922	1930	B-Drug_or_compound
has	1931	1934	O
the	1935	1938	O
potential	1939	1948	O
to	1949	1951	O
inhibit	1952	1959	O
colon	1960	1965	B-Cell
cancer	1966	1972	I-Cell
cell	1973	1977	I-Cell
growth	1978	1984	O
.	1984	1985	O

